MedTrace Logo

Local Antibiotic Delivery for Community Acquired Pneumonia

NCT06859450 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-03-10

No results posted yet for this study

Summary

A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without pre-existing lung disease.

Conditions

  • Community Acquired Pneumonia (CAP)

Interventions

DRUG

Levofloxacin

Add-on treatment of inhaled Levofloxacin 240mg twice daily or placebo (saline) twice daily for up to 3 days while admitted.

DRUG

Placebo

Add-on treatment of inhaled Levofloxacin 240mg twice daily or placebo (saline) twice daily for up to 3 days while admitted.

Sponsors & Collaborators

  • Copenhagen Respiratory Research

    lead NETWORK

Principal Investigators

  • Jens-Ulrik S. Jensen, Professor, MD, phD · Copenhagen Respiratory Research, Department of Clinical medicine Copenhagen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-04
Primary Completion
2025-09-01
Completion
2028-09-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06859450 on ClinicalTrials.gov